Antigenic epitopes with Lym-1 reactivity and uses thereof
AssigneeThe Regents of the University of California
InventorsLarry M. Rose, Claude F. Meares, Robert T. O'Donnell
Life of this patent
Estimating the term…
Abstract
This invention provides novel peptide epitopes recognized by the non-Hodgkin's B cell lymphoma reactive Lym-1 antibody. These novel peptide epitopes are capable of generating antibodies directed against Lym-1 peptide epitope expressing B-NHL cells. This invention is also directed to the treatment of B-NHL.
Claims34
A composition comprising an isolated or recombinant peptide comprising a subsequence of a Class II major histocompatibility molecule, wherein the peptide has the following properties,
- (a) having a structure comprising R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16,
- wherein R1 is Gln, Lys, or Arg;
- R2 is Arg;
- R3 and R4 are members independently selected from the group consisting of all amino acids;
- R5 is Ala, Glu, Asp, Val, Leu or Ile;
- R6 and R7 are members independently selected from the group consisting of all amino acids;
- R8 is Thr;
- R9, R10, R11, R12, R13, R14 and R15 are members independently selected from the group consisting of all amino acids;
- and, R16 is Val;
- (b) capable of generating an immune response to a non-Hodgkin's B cell lymphoma cell.
An immunogenic composition capable of eliciting an immunogenic response directed to a polypeptide epitope, wherein the epitope comprises an amino acid sequence having a structure comprising
- R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16,
- wherein R1 is Gln, Lys, or Arg;
- R2 is Arg;
- R3 and R4 are members independently selected from the group consisting of all amino acids;
- R5 is Ala, Glu, Asp, Val, Leu or Ile;
- R6 and R7 are members independently selected from the group consisting of all amino acids;
- R8 is Thr;
- R9, R10, R11, R12, R13, R14, and R15 are members independently selected from the group consisting of all amino acids;
- and, R16 is Val.
A method of inducing an immunogenic response directed to a polypeptide epitope, comprising administering an immunogenically effective amount of a composition comprising a polypeptide epitope to a mammal,
- wherein the epitope comprises an amino acid sequence having a structure comprising R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16,
- wherein R1 is Gln, Lys, or Arg;
- R2 is Arg;
- R3 and R4 are members independently selected from the group consisting of all amino acids;
- R5 is Ala, Glu, Asp, Val, Leu or Ile;
- R6 and R7 are members independently selected from the group consisting of all amino acids;
- R8 is Thr;
- R9, R10, R11, R12, R13, R14, and R15 are members independently selected from the group consisting of all amino acids;
- and, R16 is Val.
Dependencies are inferred from the claim text.